Volume 116, Issue 5, Pages (May 1999)

Slides:

Advertisements

Similar presentations

1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P

Advertisements

Serum immunoglobulin a from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation Tuula Halttunen, Markku Mäki.

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

Volume 117, Issue 6, Pages (December 1999)

Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn’s Disease–Like Ileitis: What is the Right Model? Fabio Cominelli,

A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis Urpo Kinnunen,

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire,

Volume 134, Issue 7, Pages (June 2008)

Quiz Page June 2007 American Journal of Kidney Diseases

Volume 123, Issue 1, Pages (July 2002)

Infliximab-induced eczematid-like purpura of Doucas and Kapetenakis∗∗Previously presented at the Chicago Dermatological Society meeting, Chicago, Ill,

Volume 114, Issue 1, Pages (January 1998)

Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh Adam Ingraffea, BA, Kevin Donohue, MD, Caroline Wilkel, MD,

Acute hepatitis induced by greater celandine (Chelidonium majus)

Volume 4, Issue 6, Pages (July 2018)

Volume 138, Issue 2, Pages (February 2010)

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab William J. Sandborn, Maria T. Abreu, Geert.

Abatacept for Crohn's Disease and Ulcerative Colitis

First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori Stephan Timm, Marco Sailer, Karl–hermann.

Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report Philip V. Hassard, Scott W. Binder, Viera.

Aggressive cutaneous infection with Mycobacterium marinum in two patients receiving anti–tumor necrosis factor-alfa agents Julie Caron, MD, Carine Michot,

Volume 135, Issue 4, Pages (October 2008)

Diagnosis of celiac sprue

Asmaa Chaudhry, MD, Stefanie A. Hirano, MD, Thomas J

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire,

Quiz Page December 2007 American Journal of Kidney Diseases

Volume 120, Issue 6, Pages (May 2001)

Volume 134, Issue 7, Pages (June 2008)

Volume 115, Issue 1, Pages (July 1998)

This month in Gastroenterology

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease Elana A. Maser, Renata Villela,

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

Cutaneous sporotrichosis: the old iodide treatment remains effective

A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis Urpo Kinnunen,

Bullous rheumatoid neutrophilic dermatosis

Miguel Regueiro, Kevin E. Kip, Leonard Baidoo, Jason M

Volume 130, Issue 2, Pages (February 2006)

Severe Constipation Clinical Gastroenterology and Hepatology

Linear IgA dermatosis after infliximab infusion for ulcerative colitis

Cytomegalovirus esophagitis in an immunocompetent host

Volume 132, Issue 5, Pages (May 2007)

Volume 119, Issue 6, Pages (December 2000)

Volume 114, Issue 2, Pages (February 1998)

Diagnosis of Colitis: Making the Initial Diagnosis

William J. Sandborn, Stefan Schreiber, Brian G

Volume 119, Issue 6, Pages (December 2000)

Volume 145, Issue 5, Pages e5 (November 2013)

Volume 132, Issue 1, Pages (January 2007)

David H. Bruining, William J. Sandborn

Volume 135, Issue 5, Pages (November 2008)

Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis Basilia Zingarelli,

Volume 117, Issue 6, Pages (December 1999)

AGA technical review on celiac sprue

Volume 114, Issue 6, Pages (June 1998)

Volume 121, Issue 5, Pages (November 2001)

Ischemic colitis during treatment with alosetron

Volume 126, Issue 2, Pages (February 2004)

Volume 142, Issue 5, Pages e2 (May 2012)

Volume 117, Issue 4, Pages (October 1999)

Volume 117, Issue 3, Pages (September 1999)

Volume 122, Issue 1, Pages (January 2002)

Volume 125, Issue 1, Pages (July 2003)

Gastroenterology Volume 124, Issue 4, (April 2003) DOI: /S (03)

Hemorrhagic bullous dermatosis caused by warfarin therapy

Predictors of response to infliximab in patients with Crohn's disease

Medical Therapy for Refractory Pediatric Crohn’s Disease

Volume 120, Issue 4, Pages (March 2001)

Volume 121, Issue 2, Pages (August 2001)

Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy Trevor Markham, MD, Ronan Mullan,

Volume 157, Issue 4, Pages e6 (October 2019)

Presentation transcript:

Volume 116, Issue 5, Pages 1029-1034 (May 1999) Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial Geert D'Haens*, Sander Van Deventer‡, Ruud Van Hogezand §, Douglas Chalmers∥, Christine Kothe‡, Filip Baert*, Tanja Braakman¶, Thomas Schaible¶, Karel Geboes*, Paul Rutgeerts* Gastroenterology Volume 116, Issue 5, Pages 1029-1034 (May 1999) DOI: 10.1016/S0016-5085(99)70005-3 Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 1 Improvement in CDAI (ΔCDAI) vs. improvement in endoscopic lesions (ΔCDEIS) in all patients. ●, Infliximab; ▴, placebo. r = 0.561; P = 0.002. Gastroenterology 1999 116, 1029-1034DOI: (10.1016/S0016-5085(99)70005-3) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 2 Examples of histological changes in ileal biopsy specimens after infliximab therapy (H&E stain; original magnification 125×). (A) Note the disturbed crypt architecture, dense inflammatory infiltrate, and epithelial damage before treatment (histology score, 8). (B) Four weeks after infliximab administration, the inflammatory infiltrate is reduced to normal levels, and the epithelial damage has been restored. Only the crypt architecture remains disturbed (histology score, 2). Gastroenterology 1999 116, 1029-1034DOI: (10.1016/S0016-5085(99)70005-3) Copyright © 1999 American Gastroenterological Association Terms and Conditions

Fig. 2 Examples of histological changes in ileal biopsy specimens after infliximab therapy (H&E stain; original magnification 125×). (A) Note the disturbed crypt architecture, dense inflammatory infiltrate, and epithelial damage before treatment (histology score, 8). (B) Four weeks after infliximab administration, the inflammatory infiltrate is reduced to normal levels, and the epithelial damage has been restored. Only the crypt architecture remains disturbed (histology score, 2). Gastroenterology 1999 116, 1029-1034DOI: (10.1016/S0016-5085(99)70005-3) Copyright © 1999 American Gastroenterological Association Terms and Conditions